Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Vasc Endovascular Surg ; 57(6): 592-598, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: covidwho-2260910

RESUMEN

OBJECTIVE: Assess heterogeneity within patients with resolved COVID-19 to broaden the vision about post-discharge thrombotic cases and postulate possible related mechanisms in search of better anticoagulation guidelines. This study details patients' characteristics, medical history, treatment, and outcomes of readmitted patients with late acute thrombosis through a systematic review of the literature and patients from our academic center database. METHODS: We extracted the records of patients readmitted for venous thrombosis complications after discharge from the database of the first 2000 patients admitted with COVID-19 in our academic center; we also performed a systematic review of the literature using the Medical Subject Headings terms "late thrombosis," "COVID-19," + "venous thrombosis" in PubMed and Google Scholar according to PRISMA guideline. RESULTS: The literature review found 20 patients suitable for review matching the inclusion criteria. These patients were added to those in our database, summing up a total of 26 patients. The median age was 50 years old, 76.9% were male, and most were overweight or had grade 1 obesity (n = 11, 42.3%). None had a previous thrombotic history, but 50% had an underlying comorbidity. Thrombotic events presented on a median of 20 days (range: 4-150 days) from discharge. Pulmonary embolisms occurred in 23 patients (88.46%), deep vein thrombosis in 4, mesenteric thrombosis, and cerebral venous thrombosis in 1, respectively. CONCLUSION: This study found that most patients readmitted for thrombotic events after COVID-19 discharge were middle-aged men with Venous Thrombo Embolism events.


Asunto(s)
COVID-19 , Embolia Pulmonar , Trombosis , Trombosis de la Vena , Persona de Mediana Edad , Humanos , Masculino , Femenino , COVID-19/complicaciones , Readmisión del Paciente , Cuidados Posteriores , Resultado del Tratamiento , Alta del Paciente , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/epidemiología , Trombosis de la Vena/terapia , Embolia Pulmonar/diagnóstico por imagen , Embolia Pulmonar/epidemiología , Embolia Pulmonar/etiología , Trombosis/complicaciones , Anticoagulantes/uso terapéutico
2.
J Thromb Thrombolysis ; 55(2): 282-288, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: covidwho-2274987

RESUMEN

COVID-19 patients may develop thrombotic complications, and data regarding an association between nasopharyngeal viral load and thrombosis is scarce. The aim of our study was to evaluate whether SARS-CoV-2 nasopharyngeal viral load upon admission is a useful prognostic marker for the development of thromboembolic events in patients hospitalized for SARS-CoV-2 infection. We performed a retrospective study of all hospitalized patients with a positive PCR test for SARS-CoV2 who had deep vein thrombosis (DVT), pulmonary embolization (PE), or arterial thrombosis diagnosed during their clinical course in a single academic center. The study population was divided according to the cycle threshold (Ct) value upon admission in patients with high viral load (Ct < 25), intermediate/medium viral load (Ct 25-30), and low viral load (Ct > 30). A regression model for propensity was performed matching in a 1:3 ratio those patients who had a thrombotic complication to those who did not. Among 2,000 hospitalized COVID-19 patients, 41 (2.0%) developed thrombotic complications. Of these, 21 (51.2%) were diagnosed with PE, eight (19.5%) were diagnosed with DVT, and 12 (29.2%) were diagnosed with arterial thrombosis. Thrombotic complications occurred as frequently among the nasopharyngeal viral load or severity stratification groups with no statistically significant differences. Univariate logistic regression revealed increased odds for thrombosis only in mechanically ventilated patients OR 3.10 [1.37, 7.03] (p = 0.007). Admission SARS-CoV-2 nasopharyngeal viral loads, as determined by Ct values, were not independently associated with thromboembolic complications among hospitalized patients with COVID-19.


Asunto(s)
COVID-19 , Tromboembolia , Humanos , COVID-19/complicaciones , SARS-CoV-2 , Estudios Retrospectivos , Carga Viral , ARN Viral , Tromboembolia/diagnóstico , Tromboembolia/etiología
3.
Vasc Endovascular Surg ; 57(5): 451-455, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: covidwho-2230467

RESUMEN

BACKGROUND: The gold standard for patients with carotid body tumors (CBT) is surgical resection; nevertheless, some patients are unfit for surgery or, for other reasons, could not be operated on. Active surveillance has been known to be a reasonable strategy for these cases. This study aimed to evaluate tumor growth in unoperated patients with CBTs. METHODS: A retrospective review of all unoperated patients with CBT from a single academic hospital diagnosed between 2014 and 2021 was performed. Results of nonparametric testing were presented using the median and ranges for Mann-Whitney-U or Kruskal-Wallis. Significance was defined as a 2-tailed P < .05. RESULTS: The cohort included a total of 31 patients, with a median age of 60 years (range: 37-80 years), of which 27 (87.1%) were females. The patients live at a median altitude of 2800 meters (range: 2756-2980 meters) above sea level. Twenty (64.5%) patients had Shamblin I tumors, eight (25.8%) patients had Shamblin II tumors, and three (9.7%) patients had Shamblin III tumors. Median CBT volume at diagnosis was 14.1 cm3 (range: .9 - 213.3 cm3). Median volume at diagnosis of symptomatic tumors was substantially larger than asymptomatic tumors, 49.2 cm3 vs 7.9 cm3, respectively (P = .03). Median growth of the tumors during a median 15-month follow-up (range: 3-43 months) was 3.3 cm3 (range: 0-199.9 cm3). Overall, 77% (n = 24) of the CBTs grew at least 1 cm3. CONCLUSION: Most patients in the present study had tumor growth by at least 1 cm3, with a median tumor growth of 3.3 cm.3 In the present study tumor growth was shown to be greater than other low altitude CBT active surveillance studies; therefore, surgical resection should be recommended in patients with CBT living at high altitudes.


Asunto(s)
Tumor del Cuerpo Carotídeo , Femenino , Humanos , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Masculino , Tumor del Cuerpo Carotídeo/diagnóstico por imagen , Tumor del Cuerpo Carotídeo/cirugía , Altitud , Procedimientos Quirúrgicos Vasculares , Espera Vigilante , Resultado del Tratamiento , Estudios Retrospectivos
4.
Vascular ; : 17085381221084815, 2022 Apr 07.
Artículo en Inglés | MEDLINE | ID: covidwho-1785092

RESUMEN

OBJECTIVE: This study aims to report two cases of symptomatic extrinsic compression of the inferior vena cava and left iliac vein caused by vertebral osteophytes. METHODS: We present two case reports of extrinsic venous compression by vertebral osteophytes. Both cases were endovascularly treated, with a successful outcome. A review of the literature of this unusual condition is also presented. RESULTS: The first patient is an 80-year-old woman who presented to the vascular surgery clinic with bilateral lower extremity edema and pain. A computed-tomography angiography (CTA) revealed extrinsic compression of the inferior vena cava from enlarged osteophytes. Venography and intravascular ultrasound were performed, confirming the diagnosis. A self-expanding venous stent was successfully deployed in the inferior vena cava relieving the extrinsic compression. The edema resolved the following day and was discharged without complications. The second patient is a 61-year-old male that presented to the emergency department with a left iliofemoral deep venous thrombosis. CTA showed left iliac vein compression by a lumbar osteophyte. Percutaneous thrombectomy was successfully achieved and an expanding stent was deployed covering the entire lesion. One month after the procedure the patient died from COVID-19-associated respiratory failure. CONCLUSION: Osteophytes must be considered when dealing with extrinsic venous compression, especially in elderly people.

5.
Vascular ; 30(6): 1107-1114, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-1555439

RESUMEN

OBJECTIVE: Few studies have focused on arterial thrombosis and acute limb ischemia in COVID-19. This international registry intended to study the spectrum of clinical characteristics, therapeutic trends, and outcomes in a cohort of Ibero-Latin American patients with arterial thrombosis or acute limb ischemia and COVID-19. METHODS: Data were retrospectively obtained from 21 centers in 9 countries. Patients with proven COVID-19 and asymptomatic or symptomatic arterial thrombosis were included. COVID-19 diagnosis was established by RT-PCR assay or IgM serology plus suggestive clinical/radiographical findings. We recorded and analyzed variables related to demography, clinical presentation, therapeutic trends, and outcomes. RESULTS: Eighty one patients were included in the registry. In 38.3%, acute limb ischemia symptoms were the first manifestation of COVID-19. Non-surgical management was more frequent in severe cases than surgical interventions, 11.1% vs. 88.9%, respectively (p = 0.004). Amputation rates were similar between all COVID severity groups (p = 0.807). Treatment was classified as non-surgical, open surgical, and endovascular treatment. Further analysis revealed an equal frequency of major leg amputation between treatment groups and increased mortality in patients with non-surgical management. However, multivariate regression analysis showed that treatment choices are associated with disease severity, with significant non-surgical treatment in critical patients; thus, mortality is related to the severity and confounds treatment analysis. CONCLUSION: Arterial thrombosis can be the initial symptom of a patient presenting with COVID-19. Physicians and health workers should potentially suspect COVID-19 in acute ischemia cases without a known risk factor or embolic cause. More experimental and clinical research is required to understand the complex phenomenon of arterial COVID-19 induced coagulopathy fully.


Asunto(s)
Arteriopatías Oclusivas , COVID-19 , Enfermedad Arterial Periférica , Enfermedades Vasculares Periféricas , Trombosis , Humanos , COVID-19/complicaciones , Estudios Retrospectivos , Prueba de COVID-19 , América Latina , Isquemia/diagnóstico por imagen , Isquemia/etiología , Isquemia/terapia , Enfermedades Vasculares Periféricas/cirugía , Trombosis/diagnóstico por imagen , Trombosis/etiología , Trombosis/terapia , Amputación Quirúrgica/efectos adversos , Arteriopatías Oclusivas/cirugía , Factores de Riesgo , Sistema de Registros , Recuperación del Miembro/efectos adversos , Resultado del Tratamiento
6.
Vasc Endovascular Surg ; 56(2): 144-150, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: covidwho-1477210

RESUMEN

BACKGROUND: The increasing prevalence of venous thromboembolism (VTE) among patients with coronavirus disease 2019 (COVID-19) is a matter of concern as it contributes significantly to patients' morbidity and mortality. Data regarding the optimal anticoagulation regimen for VTE prevention and treatment remain scarce. This study describes the characteristics, treatment, and outcomes of COVID-19 patients with VTE treated in a single academic center in Mexico. METHODS: We conducted a retrospective study of all patients with a positive PCR test for SARS-CoV-2 hospitalized in a single academic center in Monterrey, Mexico, between March 2020 and February 2021, with a radiologically confirmed VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE). Informed consent was obtained from each patient before reviewing their medical records. RESULTS: Of the 2000 COVID-19 hospitalized patients, 36 (1.8%) developed VTE and were included in the analysis. The median age was 60 years (range 32-88 years), and up to 78% (n = 28) were males. Most patients (n = 34, 94%) had an underlying comorbidity and 47% (n = 17) had a BMI ≥ 30 kg/m2. In most cases (n=28, 78%), VTE presented as a PE, whereas the remaining 22% (n = 8) had a DVT. The median time between hospital admission and VTE was 8 days (range 0-33 days). Regarding the thromboprophylaxis regimen, 35/36 patients received low molecular weight heparin enoxaparin on admission, most commonly at a dose of 60 mg daily (n = 19, 53%). Other complications presented were superinfection (n = 19, 53%), acute kidney injury (n = 11, 31%), and septic shock (n = 5, 14%). A total of 69% of patients (n = 25) required intensive care unit admission, and patients' overall mortality was 55.6%. CONCLUSION: VTE remains a significant cause of increased morbidity and mortality among patients with COVID-19. The strikingly high mortality among patients with VTE highlights the need for further investigation regarding the best preventive, diagnostic, and treatment approaches.


Asunto(s)
COVID-19 , Embolia Pulmonar , Tromboembolia Venosa , Adulto , Anciano , Anciano de 80 o más Años , Anticoagulantes/efectos adversos , Humanos , Masculino , México/epidemiología , Persona de Mediana Edad , Embolia Pulmonar/epidemiología , Embolia Pulmonar/terapia , Estudios Retrospectivos , SARS-CoV-2 , Resultado del Tratamiento , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/epidemiología
7.
Vascular ; 30(5): 1013-1016, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: covidwho-1367664

RESUMEN

BACKGROUND/OBJECTIVE: Deep vein thrombosis and pulmonary embolism have been described as complications in previously diagnosed COVID-19 patients, especially in those admitted in critical ill units, but, to our knowledge, there is no report of venous thromboembolism in an otherwise asymptomatic COVID-19 patient. METHODS: We report the case of a 22-year-old female, healthy patient with pulmonary embolism (Pulmonary Embolism Severity Index Score 22 points, low risk) and extensive proximal deep vein thrombosis as a unique clinical manifestation of the new coronavirus disease. RESULTS: The patient had no risk factors and no familial history of venous thromboembolism. All thrombophilia markers were negative. The patient was treated as first by an independent vascular team, performing vena cava filter placement and open thrombectomy. Her symptoms worsened, and after 3 weeks, she underwent US-enhanced thrombolysis and mechanical thrombectomy. She was isolated for 10 days and did not develop any other clinical manifestation of COVID-19 disease. During follow-up, she remained asymptomatic and complete patency of the venous system was achieved. Full oral anticoagulation was conducted for 6 months. CONCLUSION: COVID-19 appears to be a multi-symptomatic disease, and venous thromboembolism without any other previous described COVID-19 symptom could be considered one of its diverse clinical presentations and RT-PCR for SARS-CoV-2 tests emerge to be mandatory in patients with otherwise unexpected venous thrombosis.


Asunto(s)
COVID-19 , Embolia Pulmonar , Filtros de Vena Cava , Tromboembolia Venosa , Trombosis de la Vena , Adulto , Anticoagulantes/uso terapéutico , COVID-19/complicaciones , Femenino , Humanos , Embolia Pulmonar/diagnóstico por imagen , Embolia Pulmonar/etiología , Embolia Pulmonar/terapia , SARS-CoV-2 , Tromboembolia Venosa/etiología , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/etiología , Trombosis de la Vena/terapia , Adulto Joven
8.
Vascular ; 30(1): 146-150, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: covidwho-1067153

RESUMEN

BACKGROUND: Academic interaction with mentors has almost become minimal due to the current pandemic of COVID-19. The objective of this study is to introduce how a group of vascular surgery residencies joined forces to improve surgical education in times of COVID-19. METHODS: On May 2020, a group of Hispanic American vascular residency programs created webinar sessions of arterial and venous clinical cases among vascular residents across Latin America and Europe. Participants were surveyed via email. Questions were about the perceived quality and utility of the webinars; answers were stratified into negative (disagree), neutral, and positive (agree). RESULTS: There have been 60 sessions and 118 clinical cases presented. The survey was answered by 106 participants, 82 males (78.8%) and 24 women (23.0%). Fifty-four (51.9%) were board-certified vascular surgeons, 49 (47.1%) vascular surgery residents, and 2 (1.9%) general surgery residents. Mean age of the participants was 41.5 years (range: 25-74 years). Mean years of vascular surgery practice or experience were 11.2 years (range: 0-45 years). The residency programs involved in this project were from 13 different countries. Most answers received were positive for both perceived quality and utility of the webinars. CONCLUSION: Globalization and technology provide an opportunity for international education, with the goal of building well-rounded and academic vascular surgeons. This group is just the beginning of a large collaborative group among Hispanic American countries, hoping that more residency programs will join, with the aim of breaking borders in the education of vascular surgery.


Asunto(s)
COVID-19 , Cirugía General , Internado y Residencia , Cirujanos , Adulto , Anciano , Educación de Postgrado en Medicina , Femenino , Cirugía General/educación , Humanos , Masculino , Persona de Mediana Edad , SARS-CoV-2 , Cirujanos/educación , Encuestas y Cuestionarios
9.
Cir Cir ; 88(6): 794-798, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-976693

RESUMEN

In late December 2019, COVID-19, a new emerging disease, quickly spread in Wuhan, China. The WHO formally declared it a pandemic and a health emergency on March 11th, 2020. The objective of this article is to specify and list key points in relation to the recommendations issued by the different colleges, and global surgical societies, for the benefit of the Mexican medical and surgical community. Based on scientific evidence, we make recommendations for medical consultations, surgical and endoscopic procedures, hospital infrastructure, and surgical services, in addition to a proposal to reopen surgical services and elective procedures related to the COVID-19 pandemic. The time to take leadership in healthcare where the national health system together with academic societies, universities and private initiative join forces to combat the pandemic has arrived. It is convenient to form collaboration groups of experts in the different specialties that through innovation in health and education, with evidence-based medicine, efficiency of operational costs and tools such as telemedicine, allow us to return to daily surgical procedures, reestablishing the surgery services as soon as possible.


A finales de diciembre de 2019, la COVID-19, una nueva enfermedad emergente, rápidamente se propagó en Wuhan, China. La Organización Mundial de la Salud la declaró formalmente una pandemia y emergencia sanitaria el 11 de marzo de 2020. El objetivo de este artículo es precisar y enumerar los puntos clave en relación a las recomendaciones emitidas por los distintos colegios, y sociedades quirúrgicas globales, para beneficio de la comunidad médica y quirúrgica mexicana. De acuerdo con la evidencia científica, se realizan recomendaciones para las consultas médicas, los procedimientos quirúrgicos y endoscópicos, la infraestructura hospitalaria y los servicios de cirugía, además de una propuesta a la reapertura para procedimientos quirúrgicos en torno a la pandemia de COVID-19. El momento de tomar el liderazgo en salud en el que el sistema nacional de salud y las sociedades académicas, las universidades y la iniciativa privada sumen esfuerzos para combatir la pandemia ha llegado. Es conveniente formar grupos de colaboración de expertos en las distintas especialidades que, por medio de innovación en salud y educación, apego a la medicina basada en la evidencia, eficiencia de costos operacionales y herramientas como la telemedicina, permitan regresar a los procedimientos quirúrgicos cotidianos y la operación de los servicios de cirugía se reestablezca a la brevedad.


Asunto(s)
COVID-19/epidemiología , COVID-19/prevención & control , Procedimientos Quirúrgicos Electivos , Liderazgo , SARS-CoV-2 , COVID-19/diagnóstico , Prueba Serológica para COVID-19 , Causas de Muerte , Enfermedad Crónica , Endoscopía , Medicina Basada en la Evidencia , Humanos , México , Grupo de Atención al Paciente , Guías de Práctica Clínica como Asunto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA